Ocugen Inc
$ 1.28
3.23%
07 Aug - close price
- Market Cap 420,497,000 USD
- Current Price $ 1.28
- High / Low $ 1.30 / 1.25
- Stock P/E N/A
- Book Value 0.02
- EPS -0.23
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.68 %
- ROE -6.60 %
- 52 Week High 2.73
- 52 Week Low 0.96
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$12.17
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-05 | 2026-03-04 | 2025-11-05 | 2025-08-01 | 2025-05-09 | 2025-03-05 | 2024-11-08 | 2024-08-08 | 2024-05-13 | 2024-03-26 | 2023-11-09 |
| Reported EPS | -0.07 | -0.06 | -0.06 | -0.07 | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | -0.03 | -0.06 |
| Estimated EPS | -0.05 | -0.05 | -0.056 | -0.06 | -0.06 | -0.06 | -0.0533 | -0.05 | -0.05 | -0.06 | -0.06 | -0.07 |
| Surprise | -0.02 | -0.01 | -0.004 | -0.01 | 0.01 | 0.01 | 0.0033 | 0 | 0.01 | 0.01 | 0.03 | 0.01 |
| Surprise Percentage | -40% | -20% | -7.1429% | -16.6667% | 16.6667% | 16.6667% | 6.1914% | 0% | 20% | 16.6667% | 50% | 14.2857% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCGN
2026-08-07 14:11:14
State Street Corporation has reported a 6.3% beneficial ownership stake in Ocugen Inc., amounting to 21,469,307 shares of common stock as of June 30, 2026. The filing, a Schedule 13G, indicates that State Street holds shared voting power over 21,055,589 shares and shared dispositive power over all 21,469,307 shares, primarily through its asset management subsidiaries. This disclosure highlights a significant passive investment by State Street in Ocugen.
2026-08-06 21:27:00
Ocugen Inc. (OCGN) stock decreased by 3.13% on Thursday, closing at $1.24. This decline occurred during a generally negative trading session where the S&P 500 Index and Dow Jones Industrial Average also fell. This marks the second consecutive day of losses for Ocugen.
2026-08-06 19:11:14
Ocugen provided a business update along with its second-quarter 2026 financial results. This press release likely details the company's progress on its pipeline, clinical trials, and financial performance over the past quarter. Investors and stakeholders will look to this update for insights into Ocugen's operational achievements and financial health.
2026-08-06 19:11:14
Ocugen, Inc. reported its second quarter 2026 financial results, highlighting significant advancements in its gene therapy programs for blindness diseases. Key updates include FDA clearance for OCU410 Phase 3 trial in geographic atrophy, RMAT designation for OCU410, and a binding term sheet for OCU400 in the MENA region. The company also secured $130.0 million in convertible senior notes financing, extending its cash runway into 2028.
2026-08-06 16:10:39
Ocugen (NASDAQ: OCGN), a gene therapy biotechnology company, reported a net loss of $44.1 million for the first half of 2026 and $24.9 million for Q2 2026. Despite raising $112.5 million in net proceeds from a $130.0 million convertible senior notes offering and increasing cash to $100.1 million, the company disclosed substantial doubt about its ability to continue as a going concern within one year. Ocugen plans to seek shareholder approval on September 21, 2026, to increase authorized shares, which is necessary for the conversion of its new senior convertible notes.
2026-08-06 12:10:39
Ocugen reported second-quarter 2026 results, with collaborative arrangement revenue of $1.49 million and a net loss of $0.07 per share. The company held $100.4 million in cash as of June 30, 2026, and completed a $130.0 million convertible senior notes offering, extending its cash runway into 2028. Key business highlights include FDA clearance for the Phase 3 ArMaDa3 trial for OCU410 and progress on late-stage programs for OCU400 and OCU410ST.
